Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

NCT06920004 is registered in ClinicalTrials.gov with argenx as lead sponsor.

NCT NCT06920004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06920004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
Lead sponsor
argenx
Phase
Phase 3
Overall status
Recruiting
Start date
August 22, 2025
Completion date
September 30, 2030
Enrollment
218 (estimated)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyneuropathy, cidp, cidp - chronic inflammatory demyelinating polyneuropathy